Dc-Med Michal Kowalski sp.k.

At Dc-Med Michal Kowalski sp.k., investigators are advancing therapies for inflammatory bowel conditions such as Crohn's disease and ulcerative colitis, aiming to enhance long‑term disease control and patient quality of life.

• Evaluation of novel oral agents for induction and maintenance therapy
• Comparative studies of biosimilars versus reference biologics
• Assessment of safety and durability of targeted monoclonal antibodies

The site supports 14 active studies with a multidisciplinary team, seeking more effective and safer treatment options for digestive system disorders.

Clinical research at the centre includes trials on thyroid eye disease, exploring innovative biologic agents to reduce eye bulging and improve visual function.

• Testing of subcutaneous monoclonal antibodies for disease activity reduction
• Measurement of proptosis response and quality‑of‑life outcomes
• Early‑phase safety profiling of emerging ocular therapeutics

These studies reflect the site’s commitment to advancing care for patients with complex orbital inflammation.

The hospital is conducting investigations into conditions such as knee osteoarthritis, psoriatic arthritis and chronic low‑back pain, with the goal of delivering new pain‑relieving and disease‑modifying options.

• Evaluation of biologic therapies for psoriatic arthritis activity
• Assessment of adjunctive treatments to improve joint function in osteoarthritis
• Dose‑response studies of non‑opioid analgesics for non‑specific low back pain

By integrating rheumatology and pain management expertise, the site aims to reduce disability and enhance daily living for affected individuals.

Research efforts include a focus on diabetic peripheral neuropathic pain, where novel inhaled cannabis formulations are being examined for their potential to alleviate chronic neuropathic discomfort.

• Randomized evaluation of cannabinoid aerosol versus placebo
• Monitoring of pain intensity and functional improvement over 16 weeks
• Safety assessment of repeated inhalation in a diabetic cohort

The program seeks to expand therapeutic choices for patients whose neuropathic pain is refractory to standard medications.

Studies targeting obesity and related metabolic risk factors are underway, testing agents that may aid weight reduction while monitoring cardiovascular safety.

• Investigation of weight‑loss compounds in conjunction with diet and exercise
• Evaluation of cardiovascular outcome endpoints in overweight participants
• Long‑term tolerability monitoring of metabolic modulators

These trials reflect a broader strategy to address the growing burden of metabolic disease in the region.

The facility is also engaged in research on psoriatic arthritis, a condition that bridges dermatology and rheumatology, with studies designed to assess newer biologic agents for joint and skin symptom relief.

• Comparative efficacy of subcutaneous biologics versus standard care
• Use of ACR50 response criteria to gauge treatment success
• Extension studies focusing on sustained safety and effectiveness

Through these investigations, the site aims to broaden therapeutic options for patients suffering from both skin and joint manifestations.